The results obtained in a mouse tumor model documenting a trend towards an enhanced NK cell recruitment into CXCL10-mucin-GPI treated lymphoma nodules suggested that the positive effects hold true also in vivo in a tumor setting. This evidence concerns the gene CXCL10 and lymphoma.